دورية أكاديمية
أعرض في EDS

Super enhancer lncRNAs: a novel hallmark in cancer.

التفاصيل البيبلوغرافية
العنوان: Super enhancer lncRNAs: a novel hallmark in cancer.
المؤلفون: Song P; Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, 310006, Zhejiang Province, China.; Key Laboratory of Integrated Traditional Chinese and Western Medicine for Biliary and Pancreatic Diseases of Zhejiang Province, Hangzhou, 310006, China.; Hangzhou Institute of Digestive Diseases, Hangzhou, 310006, China., Han R; Department of emergency, Affiliated Hangzhou First People's Hospital, Westlake University, Hangzhou, 310006, Zhejiang Province, China., Yang F; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, 310006, Zhejiang Province, China. jacobyoung@zju.edu.cn.
المصدر: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Apr 02; Vol. 22 (1), pp. 207. Date of Electronic Publication: 2024 Apr 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101170464 Publication Model: Electronic Cited Medium: Internet ISSN: 1478-811X (Electronic) Linking ISSN: 1478811X NLM ISO Abbreviation: Cell Commun Signal Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : BioMed Central, c2003-
مواضيع طبية MeSH: RNA, Long Noncoding*/genetics , Neoplasms*/genetics, Humans ; Super Enhancers ; Enhancer Elements, Genetic/genetics ; Transcription Factors/genetics
مستخلص: Super enhancers (SEs) consist of clusters of enhancers, harboring an unusually high density of transcription factors, mediator coactivators and epigenetic modifications. SEs play a crucial role in the maintenance of cancer cell identity and promoting oncogenic transcription. Super enhancer lncRNAs (SE-lncRNAs) refer to either transcript from SEs locus or interact with SEs, whose transcriptional activity is highly dependent on SEs. Moreover, these SE-lncRNAs can interact with their associated enhancer regions in cis and modulate the expression of oncogenes or key signal pathways in cancers. Inhibition of SEs would be a promising therapy for cancer. In this review, we summarize the research of SE-lncRNAs in different kinds of cancers so far and decode the mechanism of SE-lncRNAs in carcinogenesis to provide novel ideas for the cancer therapy.
(© 2024. The Author(s).)
References: BMC Cancer. 2021 Feb 23;21(1):187. (PMID: 33622275)
J Thorac Oncol. 2023 Feb;18(2):143-157. (PMID: 36379355)
Mol Ther Nucleic Acids. 2021 Nov 03;26:1351-1363. (PMID: 34853732)
Mol Cancer Ther. 2023 Aug 1;22(8):936-946. (PMID: 37294884)
Front Immunol. 2022 Jan 27;13:803355. (PMID: 35154117)
Cell. 2017 Mar 9;168(6):1000-1014.e15. (PMID: 28283057)
Adv Sci (Weinh). 2020 Feb 16;7(7):1902926. (PMID: 32274304)
Gut. 2017 Aug;66(8):1358-1368. (PMID: 27196599)
Cancer Res. 2021 Oct 15;81(20):5190-5201. (PMID: 34353856)
Clin Cancer Res. 2020 Jun 1;26(11):2681-2692. (PMID: 31937612)
Cancer Cell. 2018 Mar 12;33(3):512-526.e8. (PMID: 29533787)
Gastroenterology. 2020 Oct;159(4):1311-1327.e19. (PMID: 32619460)
Signal Transduct Target Ther. 2021 Feb 18;6(1):68. (PMID: 33597534)
Cancer Res. 2023 Dec 15;83(24):4080-4094. (PMID: 37756562)
Oncologist. 2024 Jan 5;29(1):e131-e140. (PMID: 37531083)
Int J Mol Sci. 2022 Jan 12;23(2):. (PMID: 35054996)
J Hematol Oncol. 2022 Aug 18;15(1):114. (PMID: 35982471)
Theranostics. 2020 Aug 29;10(23):10823-10837. (PMID: 32929382)
Pharmacol Ther. 2019 Jul;199:129-138. (PMID: 30885876)
J Cell Mol Med. 2018 Feb;22(2):1292-1301. (PMID: 29083085)
J Med Chem. 2021 Oct 14;64(19):14247-14265. (PMID: 34543572)
Nature. 2012 Sep 6;489(7414):101-8. (PMID: 22955620)
Nat Methods. 2015 May;12(5):453-7. (PMID: 25822800)
Nat Commun. 2018 Sep 6;9(1):3619. (PMID: 30190462)
Exp Mol Med. 2020 May;52(5):713-723. (PMID: 32382065)
Cancer Res. 2016 Nov 1;76(21):6320-6330. (PMID: 27803105)
Nat Commun. 2021 Jul 27;12(1):4560. (PMID: 34315876)
Biomed Pharmacother. 2022 May;149:112888. (PMID: 35367753)
Int J Mol Sci. 2023 Jan 19;24(3):. (PMID: 36768307)
Cancer Lett. 2017 Aug 28;402:100-109. (PMID: 28576751)
Nat Commun. 2020 Apr 14;11(1):1833. (PMID: 32286255)
Hum Genomics. 2023 Mar 31;17(1):33. (PMID: 37004060)
Cancer Cell. 2017 May 8;31(5):635-652.e6. (PMID: 28434841)
Nucleic Acids Res. 2019 May 7;47(8):3921-3936. (PMID: 30805632)
Clin Cancer Res. 2020 Feb 15;26(4):922-934. (PMID: 31699827)
Annu Rev Biophys. 2017 May 22;46:505-529. (PMID: 28375731)
Clin Cancer Res. 2016 May 15;22(10):2470-81. (PMID: 26631615)
Biochem Biophys Res Commun. 2020 May 21;526(1):128-134. (PMID: 32199616)
Front Oncol. 2022 Mar 03;12:780493. (PMID: 35311149)
Cell. 2014 Nov 20;159(5):1126-1139. (PMID: 25416950)
Cells. 2018 Oct 09;7(10):. (PMID: 30304769)
Annu Rev Biochem. 2020 Jun 20;89:213-234. (PMID: 32197056)
JCO Precis Oncol. 2023 Sep;7:e2300235. (PMID: 37797273)
Mol Aspects Med. 2022 Aug;86:101097. (PMID: 35400524)
Nature. 2015 Oct 8;526(7572):273-276. (PMID: 26416749)
Cancer Metastasis Rev. 2020 Sep;39(3):805-823. (PMID: 32385714)
Mol Cancer. 2020 Apr 11;19(1):74. (PMID: 32278350)
Cell. 2013 Apr 11;153(2):320-34. (PMID: 23582323)
Haematologica. 2018 Dec;103(12):2049-2058. (PMID: 30076183)
Cell. 2015 Sep 24;163(1):174-86. (PMID: 26406377)
Cancer Metastasis Rev. 2023 Jun;42(2):471-480. (PMID: 37059907)
Nat Commun. 2021 Jun 25;12(1):3974. (PMID: 34172737)
Clin Transl Med. 2023 Sep;13(9):e1361. (PMID: 37658588)
Blood Adv. 2020 Jul 28;4(14):3316-3328. (PMID: 32717030)
Trends Genet. 2017 Oct;33(10):660-662. (PMID: 28778681)
Cell Stem Cell. 2018 Aug 02;23(2):276-288.e8. (PMID: 30033119)
Cancer Res. 2017 Dec 1;77(23):6614-6626. (PMID: 28951465)
Gastroenterology. 2018 Jun;154(8):2137-2151.e1. (PMID: 29454790)
Breast Cancer Res. 2021 Oct 30;23(1):101. (PMID: 34717732)
Front Cell Dev Biol. 2022 Mar 24;10:853652. (PMID: 35399501)
Cell Death Dis. 2020 Aug 21;11(8):673. (PMID: 32826850)
RNA. 2017 Nov;23(11):1729-1742. (PMID: 28839111)
Adv Sci (Weinh). 2020 Feb 11;7(7):1902880. (PMID: 32274301)
J Exp Clin Cancer Res. 2021 Oct 25;40(1):337. (PMID: 34696771)
Neuroscientist. 2023 Apr;29(2):166-176. (PMID: 34612730)
Oncogene. 2020 Oct;39(42):6556-6571. (PMID: 32917955)
Nat Rev Cancer. 2020 Jun;20(6):303-322. (PMID: 32300195)
Clin Epigenetics. 2023 Jan 31;15(1):17. (PMID: 36721155)
Nat Commun. 2017 Feb 07;8:14400. (PMID: 28169291)
J Immunother Cancer. 2021 Mar;9(3):. (PMID: 33757986)
J Mol Cell Biol. 2021 Aug 4;13(4):295-313. (PMID: 33049031)
Sci Transl Med. 2017 Jun 21;9(395):. (PMID: 28637928)
Mol Cancer. 2023 Mar 30;22(1):64. (PMID: 36998071)
Mol Ther. 2023 Jun 7;31(6):1756-1774. (PMID: 36461633)
Respir Res. 2020 Sep 16;21(1):235. (PMID: 32938459)
Mol Cancer Ther. 2018 Jun;17(6):1156-1166. (PMID: 29545334)
Cell Death Dis. 2023 Jun 29;14(6):383. (PMID: 37385987)
Cancers (Basel). 2022 Aug 17;14(16):. (PMID: 36010973)
Cell Death Dis. 2023 Aug 24;14(8):551. (PMID: 37620336)
Mol Cancer. 2020 Oct 1;19(1):146. (PMID: 33004065)
Cell Death Dis. 2020 May 5;11(5):318. (PMID: 32371868)
EMBO J. 2019 Apr 1;38(7):. (PMID: 30842097)
Pharmaceuticals (Basel). 2023 Jan 29;16(2):. (PMID: 37259348)
Nature. 2014 Jul 31;511(7511):616-20. (PMID: 25043025)
Trends Cancer. 2017 Apr;3(4):269-281. (PMID: 28718439)
Proc Natl Acad Sci U S A. 2020 Sep 15;117(37):22849-22857. (PMID: 32855301)
Database (Oxford). 2019 Jan 1;2019:. (PMID: 30806704)
Front Genet. 2022 Sep 20;13:992444. (PMID: 36204307)
Cell Res. 2014 May;24(5):513-31. (PMID: 24662484)
Lancet Haematol. 2016 Apr;3(4):e186-95. (PMID: 27063977)
iScience. 2020 Nov 24;23(12):101857. (PMID: 33344916)
Cell Death Dis. 2022 Apr 23;13(4):401. (PMID: 35461306)
Clin Cancer Res. 2019 Oct 15;25(20):6195-6205. (PMID: 31358538)
Lancet Haematol. 2016 Apr;3(4):e196-204. (PMID: 27063978)
J Med Chem. 2022 Jan 27;65(2):1458-1480. (PMID: 34726887)
Mol Oncol. 2020 Sep;14(9):2203-2230. (PMID: 32460441)
Int J Mol Sci. 2018 Feb 16;19(2):. (PMID: 29462945)
Int J Biol Sci. 2020 Jul 19;16(14):2628-2647. (PMID: 32792861)
Adv Drug Deliv Rev. 2015 Jan;81:169-83. (PMID: 25220355)
Cancer Res. 2019 Feb 1;79(3):572-584. (PMID: 30482773)
Cancer Res. 2019 Jul 1;79(13):3479-3491. (PMID: 31064851)
Front Oncol. 2021 Oct 15;11:760789. (PMID: 34722316)
Oncogene. 2020 Jan;39(3):651-663. (PMID: 31530935)
Cancers (Basel). 2022 Aug 09;14(16):. (PMID: 36010849)
Oncogene. 2014 May 29;33(22):2928-37. (PMID: 23792448)
Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188353. (PMID: 32112817)
Mol Cancer. 2018 Nov 22;17(1):164. (PMID: 30466442)
NPJ Precis Oncol. 2020 Feb 12;4:2. (PMID: 32128448)
Brief Bioinform. 2021 Mar 22;22(2):1929-1939. (PMID: 32047897)
Cancer Sci. 2022 Dec;113(12):4092-4103. (PMID: 36047964)
Cell Death Dis. 2017 Oct 5;8(10):e3073. (PMID: 28981093)
Cancer Lett. 2022 Jan 1;524:206-218. (PMID: 34688842)
Theranostics. 2016 Jan 01;6(2):219-30. (PMID: 26877780)
معلومات مُعتمدة: 82202876 National Natural Science Foundation of China; LQ23H160046 Natural Science Foundation of Zhejiang Province; 2023RC225 Medical and Health Research Project of Zhejiang Province
فهرسة مساهمة: Keywords: BRD4; CDK; Cancer; SE-lncRNA; Super enhancer
المشرفين على المادة: 0 (RNA, Long Noncoding)
0 (Transcription Factors)
تواريخ الأحداث: Date Created: 20240402 Date Completed: 20240404 Latest Revision: 20240406
رمز التحديث: 20240406
مُعرف محوري في PubMed: PMC10986047
DOI: 10.1186/s12964-024-01599-6
PMID: 38566153
قاعدة البيانات: MEDLINE
الوصف
تدمد:1478-811X
DOI:10.1186/s12964-024-01599-6